Implications of Recent Results of Long Term Multifactorial Primary Prevention of Cardiovascular Diseases

References

• Wilhelmson L, Berglund G, Elmfeldt D, et al. The multifactorial primary prevention trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279–88
   Google Scholar
• Salonen J T, Puska P, Mustaniemi H. Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–77 in North Karelia. Br Med J 1979; 2: 1178–83
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465–77
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1986; 58: 1–13
   PubMed Web of Science ®Google Scholar
• WHO European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancer 1986; i: 869–72
   Google Scholar
• Hjermann I, Byre Velve K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo study group of a randomised trial in healthy men. Lancet 1981; ii: 1303–10
   Google Scholar
• Miettinen T A, Huttunen J K, Naukkarinen V, et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1985; 254: 2097–102
   PubMed Web of Science ®Google Scholar
• Helgeland A. Treatment of mild hypertension: A five year controlled drug trial: The Oslo study. Am J Med 1980; 69: 725–32
   PubMed Web of Science ®Google Scholar
• Komitzer M, DeBacker G, Dramaix M, et al. Belgian heart disease prevention project: incidence and mortality results. Lancet 1983; i: 1066–70
   Google Scholar
• Miettinen T A, Huttunen J K, Naukkarinen V, Strandberg T, Vanhanen H. Long-term use of probucol in the multifactorial primary prevention of vascular disease. Am J Cardiol 1986; 57: 49H–54H
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 28: 335–71
   Google Scholar
• Committee of principal investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; ii: 600–4
   Google Scholar
• Muldoon M F, Manuck S B, Matthews K A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301: 309–14
   PubMed Web of Science ®Google Scholar
• The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
   PubMed Web of Science ®Google Scholar
• Carlson L A, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405–18
   PubMed Web of Science ®Google Scholar
• Hjermann I, Holme I, Leren P. Oslo study diet and antismoking trial. Results after 102 months. Am J Med 1986; 80(suppl 2A)7–11
   PubMedGoogle Scholar
• DeBacker G, Kornitzer M, Dramaix M, et al. The Belgian heart disease prevention project: 10-year mortality follow-up. Eur Heart J 1988; 9: 238–42
   Google Scholar
• The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. JAMA 1990; 263: 1795–801
   PubMed Web of Science ®Google Scholar
• The Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990; 82: 1616–28
   Google Scholar
• Strandberg T E, Salomaa V V, Naukkarinen V A, Vanhanen H T, Sarna S J, Miettinen T A. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991; 266: 1225–9
   PubMed Web of Science ®Google Scholar
• Canner P L, Berge K G, Wenger N K, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55
   PubMed Web of Science ®Google Scholar
• Haynes R B. Multiple Risk Factor Intervention Trial revisited. ACP Journal Club 1991; 114(3)71
   Google Scholar
• Berglund G. Interpreting data from the MRFIT. Circulation 1991; 6: 2608
   Google Scholar
• Naukkarinen V A, Strandberg T E, Vanhanen H T, Salomaa V V, Sarna S J, Miettinen T A. Mortality rates after multifactorial primary prevention of cardiovascular diseases. Ann Med 1989; 21: 441–6
   PubMed Web of Science ®Google Scholar
• Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. Some Oslo study data. Am J Med 1986; 80(suppl 2A)3–6
   PubMedGoogle Scholar
• Rossouw J E, Canner P L, Hulley S B. Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol lowering. N Engl J Med 1991; 325: 1813
   Google Scholar
• Buchwald H, Varco R L, Matts J P, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946–55
   PubMed Web of Science ®Google Scholar
• Samuelsson O, Wilhelmsen L, Andersson O K, Pennert K, Berglung G. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. JAMA 1987; 258: 1768–76
   PubMed Web of Science ®Google Scholar
• Neaton J D, Wentworth D, et al. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 1992; 152: 56–64
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results. I Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
   Google Scholar
• Frick M H, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyshpidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45
   PubMed Web of Science ®Google Scholar
• Rose G, Hamilton P JS, Colwell L, Shipley M J. A randomised controlled trial of anti-smoking advice: 10-year results. J Epidem Comm Health 1982; 36: 102–8
   PubMed Web of Science ®Google Scholar
• Hermanson B, Omenn G S, Kronmal R A, Gersh B J. Participants in the Coronary Artery Surgery Study. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. N Engl J Med 1988; 319: 1365–9
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38
   PubMed Web of Science ®Google Scholar
• Weber M A. Cardiovascular outcomes of treating high blood pressure. Am Heart J 1987; 114: 964–71
   Google Scholar
• Wilhelmsen L. Risk factors for coronary heart disease in perspective. European intervention trials. Am J Med 1984; 78: 37–40
   Google Scholar
• Leren P, Helgeland A, Hjermann I, Holme I. MRFIT and the Oslo Study. JAMA 1983; 249: 893–4
   PubMed Web of Science ®Google Scholar
• Mogadam M, Modest G. Letters to the Editor. JAMA 1992; 267, in press
   Google Scholar
• Strandberg T E, Salomaa V, Vanhanen H, Naukkarinen V, Sarna S, Miettinen T A. Long-term effects of probucol and beta-blocker treatment in a primary prevention trial of coronary heart disease. Eur Heart J 1989; 10: 217
   Google Scholar
• Taylor S H, Silke B, Ebbutt A, Sutton G C, Prout B J, Burley D M. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982; 307: 1293–301
   PubMed Web of Science ®Google Scholar
• Alderman M H, Madhavan S, Ooi W L, Cohen H, Sealey J E, Laragh J H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–104
   PubMed Web of Science ®Google Scholar
• Roberts W C. Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 1989; 117: 709–14
   Google Scholar
• Schaefer E J, McNamara J R, Genest J, et al. LDL particle size, lipoproteins, and apolipoproteins in premature coronary artery disease (CAD): Confounding effects of β-blockers. Circulation 1987; 76: 531, Suppl. IV
   Google Scholar
• Salomaa V. Long-term effect of primary prevention measures of coronary heart disease on the risk factor levels in middle-aged men. Dissertation, University of Helsinki, HelsinkiFinland 1988
   Google Scholar
• The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1–6
   PubMed Web of Science ®Google Scholar
• Packer M, Carver J R, Rodeheffer R J, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468–75
   PubMed Web of Science ®Google Scholar
• Anonymous. Should clinical trials carry a health warning? (Editorial). Lancet 1991; 338: 1495–6
   Google Scholar
• Siltanen P. Psychosomatic factors in coronary heart disease. Ann Clin Res 1984; 16: 142–55
   Google Scholar
• Yeung A C, Vekhstein V I, Krantz D S, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991; 325: 1551–6
   PubMed Web of Science ®Google Scholar
• Manuck S B, Kaplan J R, Matthews K A. Behavioral antecedents of coronary heart disease and atherosclerosis. Arteriosclesosis 1986; 6: 2–14
   PubMedGoogle Scholar
• Williams J K, Vita J A, Manuck S B, Selwyn A P, Kaplan J R. Psychosocial factors impair vascular responses of coronary arteries. Circulation 1991; 84: 2146–53
   PubMedGoogle Scholar
• Karasek R, Baker D, Marxer F, Ahlbom A, Theorell T. Job decision latitude, job demands, and cardiovascular disease: A prospective study of Swedish men. Am J Public Health 1981; 71: 694–705
   PubMed Web of Science ®Google Scholar
• McCormick J, Skrabanek P. Coronary heart disease is not preventable by population interventions. Lancet 1988; ii: 839–41
   Google Scholar